These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 690536)
41. [Investigation on bacteriological relapses in cases of pulmonary tuberculosis treated with INH and RFP--report of the 27th B series of controlled trials of chemotherapy. Cooperative Study Unit of Chemotherapy of Tuberculosis of National Sanatoria in Japan (CSUCTNS)]. Mochizuki K; Shigeto E; Kobayashi Y; Nagasawa S Kekkaku; 1987 May; 62(5):265-80. PubMed ID: 3626256 [No Abstract] [Full Text] [Related]
42. Preliminary results of a controlled therapeutic trail administering INH-RMP once-weekly, after--or without--an initial period of continuous treatment. Eule H; Kärnbach E; Kaluza P; Herrmann H Scand J Respir Dis Suppl; 1973; 84():153-9. PubMed ID: 4593264 [No Abstract] [Full Text] [Related]
43. [Retreatment of pulmonary tuberculosis--duration of chemotherapy]. Wada M; Seita A; Mori T; Ogata H; Sugie T; Sugita H Kekkaku; 1993 Jul; 68(7):469-78. PubMed ID: 8361115 [TBL] [Abstract][Full Text] [Related]
44. [Results of initial treatment of pulmonary tuberculosis using ethambutol, isonicotinic acid hydrazide and rifampicin]. Kesztele V; Niederkofler J Wien Med Wochenschr; 1970 Jun; 120(25):473-5. PubMed ID: 5518004 [No Abstract] [Full Text] [Related]
47. Clinical effect of rifampicin-ethambutol isoniazid on untreated pulmonary tuberculosis. Konno K; Oizumi K; Yamada S; Ogata K; Sato M Sci Rep Res Inst Tohoku Univ Med; 1972 Sep; 19(2):68-72. PubMed ID: 4649624 [No Abstract] [Full Text] [Related]
48. On the pharmacokinetics of rifampicin I: Influence of dosage and duration of treatment with intermittent administration. Iwainsky H; Winsel K; Werner E; Eule H Scand J Respir Dis; 1974; 55(4):229-36. PubMed ID: 4438983 [No Abstract] [Full Text] [Related]
49. Pulmonary disease due to Mycobacterium xenopi. Report of two cases. Bogaerts Y; Elinck W; van Renterghem D; Pauwels R; van der Straeten M Eur J Respir Dis; 1982 Jul; 63(4):298-304. PubMed ID: 7117427 [TBL] [Abstract][Full Text] [Related]
50. [Anatomic and bacteriologic testing of rifampicin effectiveness in treatment of pulmonary tuberculosis]. Morère P; Stain JP; Hubert J; Chauvet MC Rev Tuberc Pneumol (Paris); 1970; 34(3):434-8. PubMed ID: 4994941 [No Abstract] [Full Text] [Related]
51. [The short course therapies by Ryoken's method. 9 month and 12 month regimens including rifampicin (RFP) plus isoniazid (INH) in bacteriologically proved pulmonary tuberculosis]. Gomi J; Aoyagi T; Fukuhara Y; Yamaguchi T; Matsumiya T Kekkaku; 1985 Aug; 60(8):435-45. PubMed ID: 3906218 [No Abstract] [Full Text] [Related]
52. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. Nolan CM; Goldberg SV Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140 [TBL] [Abstract][Full Text] [Related]
53. Controlled therapeutic trial with the combination rifampicin-isoniazid given for six months to previously untreated patients with pulmonary tuberculosis. Dubra F Bull Int Union Tuberc; 1972 Feb; 47():37-40. PubMed ID: 4562016 [No Abstract] [Full Text] [Related]
54. Short course chemotherapy for tuberculosis. McDonagh DJ J Ky Med Assoc; 1981 Mar; 79(3):153. PubMed ID: 7276708 [No Abstract] [Full Text] [Related]
55. [Proceedings: Rifampicin in initial therapy of pulmonary tuberculosis]. Gyselen A; Cosemans J; Lacquet L; Verbist L Z Erkr Atmungsorgane Folia Bronchol; 1973; 138(1):128-35. PubMed ID: 4491709 [No Abstract] [Full Text] [Related]
56. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years]. Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281 [TBL] [Abstract][Full Text] [Related]
57. [Initial resistance to streptomycin, isoniazid, rifampicin and ethambutol in bacillus-laden tuberculosis patients at the National Center of Pneumo-physiology at Cotonou (Benin)]. Anagonou SY; Gninafon M; Josse R; Kinde-Gazard D; Tawo L; Foundohou J Bull Soc Pathol Exot; 1993; 86(2):144-7. PubMed ID: 8353477 [TBL] [Abstract][Full Text] [Related]
58. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda. Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516 [TBL] [Abstract][Full Text] [Related]
59. [Possibility to shorten the treatment of the newly detected patients with tuberculosis through continuous and intermittent application of rifampicin, myambutol and isoniasid (author's transl)]. Grujić M; Djurisić M; Mihajlović V; Jeremić V; Arsenijević V; Popovac D; Nikolić D; Radotić M; Jonev P; Nale P Plucne Bolesti Tuberk; 1977; 29(2):8-12. PubMed ID: 859943 [No Abstract] [Full Text] [Related]
60. [Short-term chemotherapy of pulmonary tuberculosis without previous treatment (results up to July 20th, 1972)]. Poppe de Figueiredo F Bull Int Union Tuberc; 1973 Jun; 48(0):139-40. PubMed ID: 4793667 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]